PhD, University of Minnesota, Twin Cities
BS, Eckerd College
My research is primarily focused on the development of novel diagnostic tests based on ‘Omic’-level profiling of patient specimens and/or mechanistic insights for pathophysiology. As the Director of the Rush Cancer Center Biorepository, I oversee the collection and annotation of patient specimens to support translational research projects and clinical trials that are ongoing in the Rush University Cancer Center. My role as the Director of the Rush Biomarker Development Core permits me to facilitate the administration of ‘state of the art’ services aimed at the discovery and development of novel biomarkers aimed at altering treatment decisions in the clinics, ranging from early cancer detection to personalized treatment selection for patients. Platforms supported include quantitative mass spectrometry and custom Luminex immunoassays that, combined with accompanying laboratory automation and skilled personnel, generate very high-throughput biomarker discovery, assay development (with analytical validation), and routine specimen processing.
In response to the global Covid-19 pandemic my laboratory has developed a novel multiplex serological test that has been submitted for FDA approval under the Emergency Use Authorization. This assay quantitatively evaluates an immune response to the SARS-CoV-2 virus, including antibodies associated with viral neutralization. Further, my lab has partnered with Dr. Jeffrey Schneider and Dr. João Mamede to provide a functional assessment of SARS-CoV-2 neutralization through an ‘in house’ developed pseudovirus neutralization assay.
Jeffrey A. Borgia, PhD. is a graduate of the Biochemistry Graduate program at the University of Minnesota where he performed research in the field of proteoglycan biosynthesis in the laboratory of Dr. Theodore R. Oegema, Jr. During his post-doctoral studies, he collaborated with Dr. Gregg B. Fields where he explored the production of matrix metalloproteinases by melanoma cells when adhered to synthetic ‘mini-collagens’ as well as tumor cell aggressiveness. In 2002, Dr. Borgia joined the faculty at Rush in the Department of Biochemistry and launched his program focused on cancer biology and the development of novel diagnostic tests with Dr. John S. Coon, IV in the Department of Pathology. He is currently continuing these studies with appointments in both the Department of Cell & Molecular Medicine and Department of Pathology.
Please visit the following link for a list of the publications listed on PubMed:
https://www.ncbi.nlm.nih.gov/myncbi/1viApd51LKn5A/bibliography/public/